BETHESDA, Md. (July 16, 2025) – Today, the Cystic Fibrosis Foundation announced an additional investment of up to $24 million ...

Expanded funding builds on the initial agreement to accelerate development of Prime Editors for Cystic Fibrosis (CF) -- -- Prime Medicin ...

BiomX has dosed the first subject in the randomised Phase IIb trial of the company’s fixed multi-phage therapy, BX004, to ...

It said that 95% of people with cystic fibrosis in England will now be eligible for modulator therapy. The new drug, also ...

Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...

Charles Kim Haskell told Newsweek he once thought he wouldn't live beyond his teenage years, but, at 31, he is enjoying his life.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...

Alfie Coe, 13, from Terrington St Clement, will be running 3km daily during his school summer holidays to raise money for the ...

Vertex Pharmaceuticals (VRTX) experienced a 4% price increase over the past month, coinciding with crucial developments in their portfolio. The recent advancement with NHS England's reimbursement ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...

Prof David Sheppard, Professor of Physiology, University of Bristol, said: ...

Hundreds of children and adults with rare forms of cystic fibrosis in England will be able to access “life-changing” new ‘triple-combination’ therapy for the very first time, the NHS has announced.